Arteriovenous (AV) Fistula Devices Market Size, Share and Growth Outlook, 2026

Arteriovenous (AV) Fistula Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Arteriovenous (AV) Fistula Devices Market size is forecast to increase from $391.65 Million in 2026 to $688.17 Million in 2034 at a CAGR of 7.3% between 2026 and 2034.

The Arteriovenous (AV) Fistula Devices market report provides detailed analysis and outlook of Arteriovenous (AV) Fistula Devices segments including By Device Type (AVF Creation Devices, AVF Maintenance Devices, AVF Monitoring Devices, Vascular Grafts and Patches), By Procedure Type (Surgical AV Fistula Creation, Endovascular AV Fistula Creation ), By End-User (Hospitals and Trauma Centers, Dialysis and Nephrology Centers, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Arteriovenous (AV) Fistula Devices Industry Overview

Innovation in Vascular Access Technologies for Hemodialysis Care

The arteriovenous (AV) fistula devices industry is undergoing significant transformation as healthcare providers seek more durable, patient-friendly, and technologically advanced vascular access solutions for hemodialysis. Increasing prevalence of end-stage renal disease (ESRD), growing demand for long-term dialysis access, and advances in regenerative medicine are driving innovation across the sector. Industry participants are focusing on improving fistula durability, reducing intervention rates, and enhancing patient outcomes through biologically engineered vascular conduits and minimally invasive access creation techniques. At the same time, digital health integration is emerging as a key trend, supporting remote monitoring and personalized management of vascular access sites.

Regenerative Medicine Advances Drive Next-Generation AV Access Solutions

Regenerative medicine is becoming a major area of innovation within the AV fistula devices market. Humacyte, Inc. continues to advance the development of its Acellular Tissue Engineered Vessel (ATEV), a bioengineered vascular conduit designed for hemodialysis access applications. Research presented at the Vascular Access Society of the Americas meeting highlighted the self-repairing characteristics of the ATEV, demonstrating its ability to maintain structural integrity while undergoing smooth muscle cell repopulation despite repeated cannulation associated with hemodialysis treatment. Since dialysis patients often require more than 300 vascular access punctures annually, the ability of engineered vessels to withstand extensive use while preserving functionality represents a significant advancement in vascular access technology. These findings support growing interest in bio-regenerative solutions capable of improving long-term access performance and reducing complications associated with traditional vascular grafts.

Clinical Progress and Evolution Toward Digital Vascular Access Management

The industry is also anticipating important clinical milestones related to next-generation vascular access devices. Humacyte is preparing to report top-line interim results from its V012 Phase 3 study focused on female patients with end-stage renal disease, with plans to pursue a supplemental Biologics License Application for the ATEV in hemodialysis access following the study results. Alongside developments in tissue-engineered vessels, minimally invasive percutaneous AV fistula creation systems such as Ellipsys and WavelinQ continue to gain adoption as alternatives to conventional open surgical procedures. These technologies offer less invasive access creation while supporting faster recovery and improved patient experience. Research efforts are also advancing toward the concept of “Vascular Access 4.0,” which combines miniaturized sensors, connected monitoring devices, and digital health platforms to enable continuous remote assessment of fistula health. This evolution supports the broader transition toward home-based dialysis care, allowing clinicians to monitor vascular access performance proactively and intervene before significant complications occur."

Arteriovenous (AV) Fistula Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Arteriovenous (AV) Fistula Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Becton, Dickinson and Company (BD), Medtronic plc (Avenu Medical), Teleflex Incorporated, Fresenius Medical Care AG & Co. KGaA, B. Braun SE, Cook Medical, Laminate Medical Technologies Ltd., Merit Medical Systems, Inc., Artivion, Inc., Poly Medicure Ltd.. The Arteriovenous (AV) Fistula Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Arteriovenous (AV) Fistula Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Arteriovenous (AV) Fistula Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Arteriovenous (AV) Fistula Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Arteriovenous (AV) Fistula Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Arteriovenous (AV) Fistula Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Arteriovenous (AV) Fistula Devices industry include- Becton, Dickinson and Company (BD), Medtronic plc (Avenu Medical), Teleflex Incorporated, Fresenius Medical Care AG & Co. KGaA, B. Braun SE, Cook Medical, Laminate Medical Technologies Ltd., Merit Medical Systems, Inc., Artivion, Inc., Poly Medicure Ltd.. The Arteriovenous (AV) Fistula Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Arteriovenous (AV) Fistula Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Arteriovenous (AV) Fistula Devices market remains one of the strongest-performing segments in the country.
The US Arteriovenous (AV) Fistula Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Arteriovenous (AV) Fistula Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Arteriovenous (AV) Fistula Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Arteriovenous (AV) Fistula Devices markets

Canada's strong Arteriovenous (AV) Fistula Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Arteriovenous (AV) Fistula Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Arteriovenous (AV) Fistula Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Arteriovenous (AV) Fistula Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Arteriovenous (AV) Fistula Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Arteriovenous (AV) Fistula Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Arteriovenous (AV) Fistula Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Arteriovenous (AV) Fistula Devices sales through 2034

France Arteriovenous (AV) Fistula Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Arteriovenous (AV) Fistula Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Arteriovenous (AV) Fistula Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Arteriovenous (AV) Fistula Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Arteriovenous (AV) Fistula Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Arteriovenous (AV) Fistula Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Arteriovenous (AV) Fistula Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Arteriovenous (AV) Fistula Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Arteriovenous (AV) Fistula Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Arteriovenous (AV) Fistula Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Arteriovenous (AV) Fistula Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Arteriovenous (AV) Fistula Devices Market Segmentation

By Device Type
AVF Creation Devices
AVF Maintenance Devices
AVF Monitoring Devices
Vascular Grafts and Patches
By Procedure Type
Surgical AV Fistula Creation
Endovascular AV Fistula Creation
By End-User
Hospitals and Trauma Centers
Dialysis and Nephrology Centers
Ambulatory Surgical Centers

Top Companies in Arteriovenous (AV) Fistula Devices Industry

Becton, Dickinson and Company (BD)
Medtronic plc (Avenu Medical)
Teleflex Incorporated
Fresenius Medical Care AG & Co. KGaA
B. Braun SE
Cook Medical
Laminate Medical Technologies Ltd.
Merit Medical Systems, Inc.
Artivion, Inc.
Poly Medicure Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa